ReviewEye and brain2016
Retinopathy of prematurity: the need for prevention.
Review in Eye and brain, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 51 citations in OpenAlex.
- HDAC3 mediates retinal endothelial cell metabolic reprogramming and angiogenesis.Acta pharmacologica Sinica · 2026Article
- Review
- Β3-Adrenergic Receptors and Prematurity-Related Diseases: A Systematic Review.Children (Basel, Switzerland) · 2025Review
- Modulation of microglial phagocytosis via the GAS6-MERTK pathway regulates pathological angiogenesis in the mouse oxygen-induced retinopathy model.Cell death & disease · 2025Article
- Retinopathy of Prematurity in Eight Portuguese Neonatal Intensive Care Units: Incidence, Risk Factors, and Progression-A Prospective Multicenter Study.Children (Basel, Switzerland) · 2024Article
- Risk factors for the time to development of retinopathy of prematurity in premature infants in Iran: a machine learning approach.BMC ophthalmology · 2024Article
- Article
- Latest Trends in Retinopathy of Prematurity: Research on Risk Factors, Diagnostic Methods and Therapies.International journal of general medicine · 2023Review
- Targeting proliferative retinopathy: Arginase 1 limits vitreoretinal neovascularization and promotes angiogenic repair.Cell death & disease · 2022Article
- Caffeine and Its Neuroprotective Role in Ischemic Events: A Mechanism Dependent on Adenosine Receptors.Cellular and molecular neurobiology · 2022Review
- Harnessing retinal phagocytes to combat pathological neovascularization in ischemic retinopathies?Pflugers Archiv : European journal of physiology · 2022Review
- β3-Adrenoceptor, a novel player in the round-trip from neonatal diseases to cancer: Suggestive clues from embryo.Medicinal research reviews · 2022Review
- The retinal vascular growth rate in babies with retinopathy of prematurity could indicate treatment need.Indian journal of ophthalmology · 2022Article
- How to prevent ROP in preterm infants in Indonesia?Health science reports · 2021Review
- Inhibition of retinal neovascularization by a PEDF-derived nonapeptide in newborn mice subjected to oxygen-induced ischemic retinopathy.Experimental eye research · 2020Article
- Retinopathy of prematurity in Rwanda: a prospective multi-centre study following introduction of screening and treatment services.Eye (London, England) · 2020Article
- Neuronal and glial regulation of CNS angiogenesis and barriergenesis.Development (Cambridge, England) · 2020Review
- Targeted Blood Metabolomic Study on Retinopathy of Prematurity.Investigative ophthalmology & visual science · 2020Article
- Trans-pars-planar illumination enables a 200° ultra-wide field pediatric fundus camera for easy examination of the retina.Biomedical optics express · 2020Article
- Longitudinal OCT and OCTA monitoring reveals accelerated regression of hyaloid vessels in retinal degeneration 10 (rd10) mice.Scientific reports · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 2 countries.
Funding
Abstract
More than 450,000 babies are born prematurely in the USA every year. The improved survival of even the most vulnerable low body weight preterm infants has, despite improving health outcomes, led to the resurgence in preterm complications including one of the major causes for blindness in children, retinopathy of prematurity (ROP). The current mainstay in ROP therapy is laser photocoagulation and the injection of vascular endothelial growth factor (VEGF) antibodies in the late stages of the disease after the onset of neovascularization. Both are proven options for ophthalmologists to treat the severe forms of late ROP. However, laser photocoagulation destroys major parts of the retina, and the injection of VEGF antibodies, although rather simple to administer, may cause a systemic suppression of normal vascularization, which has not been studied in sufficient depth. However, the use of neither VEGF antibody nor laser treatment prevents ROP, which should be the long-term goal. It should be possible to prevent ROP by more closely mimicking the intrauterine environment after preterm birth. Such preventive measures include preventing the toxic postbirth influences (eg, oxygen excess) as well as providing the missing intrauterine factors (eg, insulin growth factor 1) and are likely to also reduce other complications of premature birth as well as ROP. This review is meant to summarize the current knowledge on the prevention of ROP with a particular emphasize on the use of insulin growth factor 1 supplementation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.